SR-4835
SR-4835 is a potent, highly selective and ATP competitive dual inhibitor of CDK12/CDK13 (CDK12: IC50=99 nM, Kd=98 nM; CDK13: Kd=4.9 nM) . SR-4835 acts in synergy with DNA-damaging chemotherapy and PARP inhibitors and provokes triple-negative breast cancer (TNBC) cell death[1].
Product Specifications
CAS Number
2387704-62-1
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; CDK
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/sr-4835.html
Purity
99.82
Solubility
DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C) |H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
CN1N=CC(N2C3=NC(N4CCOCC4)=NC(NCC5=NC6=C(N5)C=C(Cl)C(Cl)=C6)=C3N=C2)=C1
Molecular Formula
C21H20Cl2N10O
Molecular Weight
499.36
Precautions
H302, H315, H319, H335
References & Citations
[1]Quereda V, et al. Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer. Cancer Cell. 2019 Oct 8. pii: S1535-6108 (19) 30424-6.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CDK12; CDK13
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Retinol Binding Protein 4 (RBP4) Monoclonal Antibody
Retinol Binding Protein 4 (RBP4) Monoclonal Antibody